Coral Laboratories Past Earnings Performance
Past criteria checks 2/6
Coral Laboratories's earnings have been declining at an average annual rate of -3%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 2.7% per year. Coral Laboratories's return on equity is 5.3%, and it has net margins of 13.8%.
Key information
-3.0%
Earnings growth rate
-3.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -2.7% |
| Return on equity | 5.3% |
| Net Margin | 13.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Coral Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 662 | 91 | 106 | 0 |
| 30 Sep 23 | 729 | 78 | 106 | 0 |
| 30 Jun 23 | 754 | 67 | 108 | 0 |
| 31 Mar 23 | 781 | 64 | 113 | 0 |
| 31 Dec 22 | 868 | 99 | 121 | 0 |
| 30 Sep 22 | 754 | 93 | 119 | 0 |
| 30 Jun 22 | 681 | 48 | 112 | 0 |
| 31 Mar 22 | 756 | 90 | 118 | 0 |
| 31 Dec 21 | 834 | 82 | 143 | 0 |
| 30 Sep 21 | 984 | 126 | 143 | 0 |
| 30 Jun 21 | 981 | 141 | 110 | 0 |
| 31 Mar 21 | 966 | 136 | 126 | 0 |
| 31 Dec 20 | 893 | 153 | 109 | 0 |
| 30 Sep 20 | 809 | 129 | 106 | 0 |
| 30 Jun 20 | 792 | 120 | 107 | 0 |
| 31 Mar 20 | 706 | 71 | 111 | 0 |
| 31 Dec 19 | 693 | 25 | 115 | 0 |
| 30 Sep 19 | 729 | 33 | 114 | 0 |
| 30 Jun 19 | 820 | 70 | 97 | 0 |
| 31 Mar 19 | 911 | 102 | 116 | 0 |
| 31 Dec 18 | 968 | 144 | 111 | 0 |
| 30 Sep 18 | 924 | 134 | 111 | 0 |
| 30 Jun 18 | 967 | 141 | 93 | 0 |
| 31 Mar 18 | 925 | 124 | 100 | 0 |
| 31 Dec 17 | 904 | 137 | 83 | 0 |
| 30 Sep 17 | 960 | 166 | 77 | 0 |
| 30 Jun 17 | 902 | 153 | 70 | 0 |
| 31 Mar 17 | 904 | 163 | 71 | 0 |
| 31 Dec 16 | 883 | 157 | 64 | 0 |
| 30 Sep 16 | 836 | 138 | 60 | 0 |
| 30 Jun 16 | 801 | 126 | 55 | 0 |
| 31 Mar 16 | 770 | 124 | 52 | 0 |
| 31 Dec 15 | 718 | 114 | 91 | 0 |
| 30 Sep 15 | 658 | 112 | 89 | 0 |
| 30 Jun 15 | 628 | 108 | 44 | 0 |
| 31 Mar 15 | 594 | 96 | 43 | 0 |
| 31 Dec 14 | 556 | 88 | 62 | 0 |
| 30 Sep 14 | 532 | 76 | 60 | 0 |
| 30 Jun 14 | 506 | 74 | 59 | 0 |
| 31 Mar 14 | 508 | 79 | 68 | 0 |
| 31 Dec 13 | 477 | 79 | 64 | 0 |
| 30 Sep 13 | 460 | 74 | 49 | 0 |
| 30 Jun 13 | 442 | 65 | 31 | 0 |
Quality Earnings: 524506 has high quality earnings.
Growing Profit Margin: 524506's current net profit margins (13.8%) are higher than last year (11.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524506's earnings have declined by 3% per year over the past 5 years.
Accelerating Growth: 524506's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 524506 had negative earnings growth (-7.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.3%).
Return on Equity
High ROE: 524506's Return on Equity (5.3%) is considered low.